3.1.1.32 arachidonyl trifluoromethyl ketone analogue - 138719 3.1.1.32 Ca2+ - 15 3.1.1.32 Cationic amphiphilic drugs - 98982 3.1.1.32 CHAPS - 1137 3.1.1.32 DFP - 923 3.1.1.32 diethyl-p-nitrophenyl phosphate - 20240 3.1.1.32 DNA containing thymine glycol - 33417 3.1.1.32 E-600 - 58859 3.1.1.32 EDTA - 21 3.1.1.32 Fe2+ - 25 3.1.1.32 Fe3+ - 70 3.1.1.32 GSK264220A - 147041 3.1.1.32 guanosine 5'-[gamma-thio]triphosphate - 31492 3.1.1.32 iodoacetic acid - 213 3.1.1.32 lauryldimethylbenzyl ammonium chloride - 100829 3.1.1.32 N-bromosuccinimide - 208 3.1.1.32 octyl-beta-glucoside - 30299 3.1.1.32 p-Diazobenzenesulfonic acid - 44646 3.1.1.32 palmitoyl trifluoromethyl ketone analogue - 138718 3.1.1.32 rabbit anti-phospholipase A antibodies - 101416 3.1.1.32 Rosenthal's inhibitor - 138720 3.1.1.32 SDS - 124 3.1.1.32 sodium deoxycholate - 549 3.1.1.32 taurodeoxycholate - 1833 3.1.1.32 tetrahydrolipstatin - 5351 3.1.1.32 Triton X-100 - 61 3.1.1.32 Tween 20 - 555 3.1.1.32 Sodium vanadate 0.01 mM, 50% inhibition 4598 3.1.1.32 DNA containing thymine glycol 0.05 mM, 50% inhibition 33417 3.1.1.32 chlorpromazine 1 mM, 50% inhibition 727 3.1.1.32 Fe3+ 1 mM, almost complete inhibition 70 3.1.1.32 dithiothreitol 1 mM, complete inhibition 45 3.1.1.32 liponox DCH 1%, i.e. polyoxyethylene alkylether 12984 3.1.1.32 Ca2+ 10 mM CaCl2, 50-60% inhibition of lysosomal enzyme 15 3.1.1.32 Ca2+ 10 mM, 20-60% increase in activity 15 3.1.1.32 EDTA 10 mM, 30-40% inhibition 21 3.1.1.32 Zn2+ 10 mM, 44% inhibition 14 3.1.1.32 NaCl 10 mM, 50% inhibition 42 3.1.1.32 Fe3+ 10 mM, 79% inhibition 70 3.1.1.32 cocaine 10 mM, below 10% residual activity 1231 3.1.1.32 NaCl 100 mM, 20-30% inhibition of lysosomal enzyme 42 3.1.1.32 Mg2+ 13.5% relative activity at 5 mM 6 3.1.1.32 KCl 2 M, inactivation of the soluble enzyme, no inactivation of the membrane-bound enzyme 79 3.1.1.32 2-mercaptoethanol 2 mM, 43% inhibition 63 3.1.1.32 SDS 2 mM, 85% inhibition 124 3.1.1.32 SDS 20.9% relative activity at 5 mM 124 3.1.1.32 Ca2+ 200 mM, 77% inhibition 15 3.1.1.32 Co2+ 43% inhibition at 2 mM 23 3.1.1.32 Fe2+ 5 mM 25 3.1.1.32 Hg2+ 5 mM 33 3.1.1.32 Cr3+ 51.4% relative activity at 5 mM 895 3.1.1.32 Zn2+ 52% relative activity at 5 mM 14 3.1.1.32 Na+ 54.7% relative activity at 5 mM 59 3.1.1.32 Cu2+ 56.8% relative activity at 5 mM 19 3.1.1.32 Ni2+ 57% inhibition at 2 mM 38 3.1.1.32 Zn2+ 66% inhibition at 2 mM 14 3.1.1.32 Fe2+ 89.2% relative activity at 5 mM 25 3.1.1.32 additional information a protein found in Bacillus subtilis specifically inhibits the phospholipase 2 3.1.1.32 Triton X-100 at high concentration 61 3.1.1.32 methyl arachidonyl fluorophosphonate blocks phospholipase A1 as well as phospholipase A2 activity 2443 3.1.1.32 Ca2+ CaCl2, slight 15 3.1.1.32 Cd2+ complete inhibition at 2 mM 52 3.1.1.32 Cu2+ complete inhibition at 2 mM 19 3.1.1.32 Fe2+ complete inhibition at 2 mM 25 3.1.1.32 EDTA complete inhibition at 5 mM 21 3.1.1.32 Mn2+ complete inhibition at 5 mM 11 3.1.1.32 Triton X-100 complete inhibition at 5 mM 61 3.1.1.32 diisopropyl fluorophosphate IC50: 8 mM 244 3.1.1.32 Al3+ inhibition of phospholipase A1 activity and lysophospholipase activity 264 3.1.1.32 Fe2+ inhibition of phospholipase A1 activity and lysophospholipase activity 25 3.1.1.32 Fe3+ inhibition of phospholipase A1 activity and lysophospholipase activity 70 3.1.1.32 additional information inhibition of RP534 PLA2 activity by nanomolar amounts of the potent, irreversible inhibitor methyl arachidonoyl fluorophosphonate and by the reversible inhibitor arachidonoyl trifluoromethylketone 2 3.1.1.32 choline plasmalogen inhibits hydrolysis of phosphatidylethanolamine 12474 3.1.1.32 ethanolamine plasmalogen inhibits hydrolysis of phosphatidylethanolamine 31450 3.1.1.32 additional information naturally occuring inhibitors of lysosomal phospholipase A are present in two of the lysosomal-soluble protein fractions obtained in the purification 2 3.1.1.32 EDTA no activity in the presence of EDTA 21 3.1.1.32 additional information not inhibitory: 0.1% Triton X-100 2 3.1.1.32 additional information PLA1 is not affected by Mg2+, Cs2+, and EDTA 2 3.1.1.32 additional information protease inhibitors, e.g. pepstatin, E 64, leupeptin or chymostatin reduce lysosomal acid phospholipase A1 activity in cultured rat hepatocytes 2 3.1.1.32 thiol reagents protected by 2-mercaptoethanol 3246 3.1.1.32 Insulin significantly reduces endothelial lipase mRNA and protein expression in a dose dependent manner 524 3.1.1.32 MgCl2 slight 196 3.1.1.32 Ca2+ slight inhibition at 2 mM 15 3.1.1.32 Mn2+ slight inhibition at 2 mM 11 3.1.1.32 di-isopropyl fluorophosphate TbPLA1 possesses an active-site serine residue, but is relatively insensitive to serine-modifying reagents such as di-isopropyl fluorophosphate and PMSF 35850 3.1.1.32 PMSF TbPLA1 possesses an active-site serine residue, but is relatively insensitive to serine-modifying reagents such as di-isopropyl fluorophosphate and PMSF 248 3.1.1.32 additional information the enzyme is not inhibited by EDTA and DTT 2 3.1.1.32 gentamycin the inhibition by aminoglycosides appears to be due to substrate depletion caused by binding of aminoglycosides to the negatively charged phospholipid and can be overcome by raising the substrate concentration 8318 3.1.1.32 tobramycin the inhibition by aminoglycosides appears to be due to substrate depletion caused by binding of aminoglycosides to the negatively charged phospholipid and can be overcome by raising the substrate concentration 939 3.1.1.32 SDS Triton enhances the inhibitory effect 124 3.1.1.32 Ca2+ up to 0.1 mM 15 3.1.1.32 2-mercaptoethanol weak inhibition 63 3.1.1.32 PMSF weak inhibition 248 3.1.1.32 Triton X-100 weak inhibition at up to 0.23% w/v 61